Loading
NASDAQHealthcareBiotechnology
Latest quote
$14.07
−$0.25 · -1.75%
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Previous close
$14.07
−$0.25 · -1.75%
Regular session · ET · Market data may be delayed.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Day range
Current $14.07
52-week range
Current $14.07
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
75
Undervalued
Sentiment
68
Bullish
Risk
51
Elevated Risk
Momentum
89
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Day range
Current $14.07
52-week range
Current $14.07
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 123.67M USD | 75.62M USD | — | — | — |
| Cost of goods sold | 8.36M USD | 8.12M USD | 6.22M USD | — | — |
| Gross profit | 115.32M USD | 67.5M USD | −6.22M USD | — | — |
| Research and development | 141.5M USD | 121.56M USD | 105.05M USD | 85.06M USD | 57.16M USD |
| Selling, general, and administrative | 36.38M USD | 35.17M USD | 32.04M USD | 27.32M USD | 15.73M USD |
| Operating expenses | 169.52M USD | 148.61M USD | 137.09M USD | 112.38M USD | 72.88M USD |
| Interest income | 12.94M USD | 10.57M USD | 9.33M USD | 3.76M USD | 46K USD |
| Interest expense | — | — | — | 3.76M USD | — |
| Depreciation and amortization | 8.36M USD | 8.12M USD | 6.22M USD | 3.75M USD | 2.13M USD |
| Operating income | −54.21M USD | −81.11M USD | −143.31M USD | −112.38M USD | −72.88M USD |
| Net income | −38.63M USD | −72.7M USD | −135.35M USD | −108.5M USD | −73.96M USD |
Company facts updated Sep 13, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$26.67
89.55% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI42.31M0.00%2.3T USD0.03%$376.31+0.82%
State Street SPDR S&P Biotech ETFXBI31.13M0.29%10.57B USD0.35%$156.2-0.40%
iShares Russell 2000 ETFIWM26.83M0.03%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF12.99M0.01%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO9.98M0.07%14.32B USD0.24%$367.63+0.54%
Avantis U.S. Small Cap Value ETFAVUV7.42M0.02%31.79B USD0.25%$124.5+0.58%
Vanguard Russell 2000 ETFVTWO6.87M0.04%17.4B USD0.06%$116.76+0.36%
iShares Biotechnology ETFIBB6.35M0.06%10.3B USD0.44%$202.93+0.14%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOAvantis U.S. Small Cap Value ETFAVUVVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
